These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3499938)

  • 1. Alpha 1-antitrypsin deficiency--a defect in secretion.
    Foreman RC
    Biosci Rep; 1987 Apr; 7(4):307-11. PubMed ID: 3499938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of amino acid substitutions at position 342 on the secretion of human alpha 1-antitrypsin from Xenopus oocytes.
    Wu Y; Foreman RC
    FEBS Lett; 1990 Jul; 268(1):21-3. PubMed ID: 2384157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xenopus oocytes can synthesise but do not secrete the Z variant of human alpha 1-antitrypsin.
    Foreman RC; Judah JD; Colman A
    FEBS Lett; 1984 Mar; 168(1):84-8. PubMed ID: 6200362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations which impede loop/sheet polymerization enhance the secretion of human alpha 1-antitrypsin deficiency variants.
    Sidhar SK; Lomas DA; Carrell RW; Foreman RC
    J Biol Chem; 1995 Apr; 270(15):8393-6. PubMed ID: 7721731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of the Lys-290--Glu-342 salt bridge in human alpha 1-antitrypsin does not prevent its synthesis and secretion.
    Foreman RC
    FEBS Lett; 1987 May; 216(1):79-82. PubMed ID: 2884131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repair of the secretion defect in the Z form of alpha 1-antitrypsin by addition of a second mutation.
    Brantly M; Courtney M; Crystal RG
    Science; 1988 Dec; 242(4886):1700-2. PubMed ID: 2904702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Recruitment-Secretory Block ("R-SB") Phenomenon and Endoplasmic Reticulum Storage Diseases.
    Callea F; Tomà P; Bellacchio E
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34202771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of the 290-342 salt bridge is not responsible for the secretory defect of the PiZ alpha 1-antitrypsin variant.
    Sifers RN; Hardick CP; Woo SL
    J Biol Chem; 1989 Feb; 264(5):2997-3001. PubMed ID: 2563374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mechanism of Z alpha 1-antitrypsin accumulation in the liver.
    Lomas DA; Evans DL; Finch JT; Carrell RW
    Nature; 1992 Jun; 357(6379):605-7. PubMed ID: 1608473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human alpha 1-antitrypsin expression in Xenopus oocytes. Secretion of the normal (PiM) and abnormal (PiZ) forms.
    Errington DM; Bathurst IC; Carrell RW
    Eur J Biochem; 1985 Dec; 153(2):361-5. PubMed ID: 3878282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The endoplasmic reticulum degradation pathway for mutant secretory proteins alpha1-antitrypsin Z and S is distinct from that for an unassembled membrane protein.
    Teckman JH; Perlmutter DH
    J Biol Chem; 1996 May; 271(22):13215-20. PubMed ID: 8662752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant disulphide bonding contributes to the ER retention of alpha1-antitrypsin deficiency variants.
    Ronzoni R; Berardelli R; Medicina D; Sitia R; Gooptu B; Fra AM
    Hum Mol Genet; 2016 Feb; 25(4):642-50. PubMed ID: 26647313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-1-antitrypsin deficiency: accumulation or degradation of mutant variants within the hepatic endoplasmic reticulum.
    Sifers RN; Finegold MJ; Woo SL
    Am J Respir Cell Mol Biol; 1989 Nov; 1(5):341-5. PubMed ID: 2700304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A selective defect in secretion of alpha 1-proteinase inhibitor PiZZ demonstrated in surrogate and primary extrahepatic cell culture.
    Perlmutter DH; Kay RM; Cole FS; Rossing TH; Van Thiel D; Colten HR
    Trans Assoc Am Physicians; 1985; 98():47-54. PubMed ID: 3879845
    [No Abstract]   [Full Text] [Related]  

  • 15. Crystallographic and cellular characterisation of two mechanisms stabilising the native fold of alpha1-antitrypsin: implications for disease and drug design.
    Gooptu B; Miranda E; Nobeli I; Mallya M; Purkiss A; Brown SC; Summers C; Phillips RL; Lomas DA; Barrett TE
    J Mol Biol; 2009 Apr; 387(4):857-68. PubMed ID: 19232354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mineralization of alpha-1-antitrypsin inclusion bodies in Mmalton alpha-1-antitrypsin deficiency.
    Callea F; Giovannoni I; Francalanci P; Boldrini R; Faa G; Medicina D; Nobili V; Desmet VJ; Ishak K; Seyama K; Bellacchio E
    Orphanet J Rare Dis; 2018 May; 13(1):79. PubMed ID: 29769092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver disease in alpha-1 antitrypsin deficiency: current understanding and future therapy.
    Teckman JH
    COPD; 2013 Mar; 10 Suppl 1():35-43. PubMed ID: 23527737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of calreticulin expression reveals a novel exosome-mediated mechanism of Z variant α
    Khodayari N; Oshins R; Alli AA; Tuna KM; Holliday LS; Krotova K; Brantly M
    J Biol Chem; 2019 Apr; 294(16):6240-6252. PubMed ID: 30833329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency.
    Burrows JA; Willis LK; Perlmutter DH
    Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1796-801. PubMed ID: 10677536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha1-antitrypsin deficiency: liver disease associated with retention of a mutant secretory glycoprotein in the endoplasmic reticulum.
    Perlmutter DH
    Methods Mol Biol; 2003; 232():39-56. PubMed ID: 12840538
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.